相关实验视频

Updated: Sep 9, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

人类T细胞白血病病毒1型:致癌潜力和疫苗开发策略

Jorge Vasconez-Gonzalez¹, Isaac A Suárez-Sangucho¹, Esteban Acosta-Muñoz¹

¹One Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.

Frontiers in cellular and infection microbiology

|September 2, 2025

概括

人类T细胞淋巴细胞病毒1型 (HTLV-1) 导致ATLL和HAM/TSP. 本综述综合了 HTLV-1 瘤发生,免疫逃避,以及对这一被忽视的逆转录病毒的有希望的疫苗策略.

科学领域:

病毒学
癌症学
免疫学

背景情况:

人类T细胞淋巴变性病毒1型 (HTLV-1) 是一种与成年T细胞白血病/淋巴瘤 (ATLL) 和HTLV-1相关的骨髓病/热带性 (HAM/TSP) 相关的逆转录病毒.
主要的ATLL风险因素包括高的前病毒载量,降低的抗Tax免疫力和可溶性互白素-2受体水平的增加.
HTLV-1 瘤发生涉及病毒基因失调,表观遗传变化和免疫逃避,与编码原型瘤基因的病毒不同.

研究的目的:

提供HTLV-1瘤发生的全面审查.
突出了像Tax和HBZ这样的病毒蛋白质在免疫规避中的作用.
批判性地检查目前的HTLV-1疫苗研发情况.

主要方法:

对HLV-1的当前知识进行综合的文献综述.
对导致HTLV-1相关疾病的分子机制的分析.
临床前疫苗策略的评估

主要成果:

HTLV-1通过复杂的机制驱动细胞转化,而不仅仅是原型瘤基因.
病毒蛋白Tax和HBZ在HTLV-1的免疫逃避策略中起着至关重要的作用.
几种候选疫苗,包括病毒载体,mRNA,和树突细胞,在临床前环境中显示出有前途.

结论:

尽管了解HTLV-1瘤发生的进展,但仍缺乏有效的预防疫苗.
目前对各种疫苗平台的研究为控制这种被忽视的逆转录病毒提供了希望.
进一步开发和评估疫苗策略对于对抗HTLV-1感染至关重要.

关键词:

一个HTLV 癌症人类T细胞白血病病毒1型免疫逃避癌症发生复原病毒病毒瘤基因

更多相关视频

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.